Anthem Biosciences Limited reported robust Q1 FY26 results, with consolidated revenue reaching INR 540.00 crores, a 60% year-on-year growth. EBITDA stood at INR 214.30 crores with a 38% margin, while PAT was INR 135.80 crores with a 24% margin. The company added two commercial molecules and expanded its custom synthesis capacity. Anthem Biosciences maintains a strong pipeline with 8 molecules in Phase 3 trials and plans further capacity expansion across its units. The management expects to maintain historical growth rates of around 20% annually, despite this quarter's exceptional performance.
Anthem Biosciences, a leading CRDMO, reported robust Q1 financial results. Consolidated Revenue from Operations increased by 59.5% to ₹5,402.09 crore. EBITDA reached ₹2,143.00 crore with a 38% margin. PAT grew by 64.8% to ₹1,358.00 crore. The CRDMO segment contributed 83.8% of total revenue. The company is expanding its capabilities in API, intermediates, formulation, biologics, and specialty chemistry services. Operational expansions include new facilities at Unit II and Unit III in Harohalli, with construction beginning on a greenfield facility at Unit IV.
Anthem Biosciences Shares Soar 27% on Stock Market Debut
Anthem Biosciences Limited made a strong market debut with shares opening at ₹723.05, a 27% premium over its IPO price of ₹570. This represents a gain of ₹153.05 per share for IPO investors. The impressive listing suggests investor confidence in the company's potential and reflects broader interest in the biosciences sector.